TVI

TVI Biotherapeutics is a clinical-stage biotechnology company focused on developing novel nanomedicines and immunotherapies for the treatment of chronic infectious diseases and cancer. The company's core technology is the Targeted Viral Immunotherapy (TVI) platform, which utilizes a proprietary nanomedicine approach to deliver DNA-based immunogens specifically to dendritic cells via the mannose receptor. Their lead candidate, TVI-HIV-1 (also known as DermaVir), is a therapeutic vaccine designed to induce high-affinity T-cell responses in patients with HIV/AIDS. Beyond infectious diseases, TVI is expanding its pipeline to include DNA-based immunotherapies for solid tumors, particularly those associated with HPV. The company operates with a focus on topical or minimally invasive delivery methods to enhance patient compliance and immune activation.